Opus Genetics (IRD) Other financing activities (2020 - 2026)
Opus Genetics (IRD) reported Other financing activities of $100000.0 for Q1 2026, down 92.92% year-over-year from $1.4 million in Q1 2025, and up 2.04% on a QoQ basis from $98000.0 in Q4 2025.
Opus Genetics (IRD) has 7 years of Other financing activities data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Other financing activities fell 92.92% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $455000.0 (down 71.28% YoY) and the FY2025 annual result came in at $2.3 million, up 891.81% from the prior year.
- Other financing activities climbed to $100000.0 in Q1 2026 per IRD's latest filing, from $98000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $1.4 million in Q1 2025 and bottomed at $12000.0 in Q4 2022.
- The 5-year median for Other financing activities is $98000.0 (2025), against an average of $173933.3.
- The widest annual swing landed in 2022, when Other financing activities plunged 93.81%; it then jumped 2216.39% in 2025.
- Tracing IRD's Other financing activities over 5 years: stood at $12000.0 in 2022, then jumped by 1333.33% to $172000.0 in 2023, then slumped by 73.26% to $46000.0 in 2024, then soared by 113.04% to $98000.0 in 2025, then rose by 2.04% to $100000.0 in 2026.
- Per Business Quant, the three latest IRD Other financing activities figures stand at $100000.0 (Q1 2026), $98000.0 (Q4 2025), and $100000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Dec 31, 2025 | 98,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 157,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 46,000.00 |
| Dec 31, 2024 | 46,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 25,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 172,000.00 |
| Dec 31, 2023 | 172,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | 194,000.00 |
| Dec 31, 2021 | 194,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Dec 31, 2020 | 300,000.00 |
| Dec 31, 2020 | 300,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |